Neil Pravin Shah, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Avenue, MSB, #1471E
San Francisco CA 94143
Phone415-514-0269
PronounsHe/Him/His
ORCID ORCID Icon0000-0003-4398-3388 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California Los AngelesM.D.1996School of Medicine
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 

    Collapse Research 
    Collapse research activities and funding
    Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.
    NIH R41CA199753Sep 23, 2015 - Aug 31, 2016
    Role: Principal Investigator
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    NIH R01CA194094Aug 1, 2015 - Jul 31, 2019
    Role: Principal Investigator
    Crenolanib and ponatinib for the treatment of FLT3 mutant AML
    NIH R01CA176091Apr 8, 2013 - Mar 31, 2018
    Role: Principal Investigator
    Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML
    NIH R01CA166616Apr 17, 2012 - Mar 31, 2017
    Role: Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. FOXA2 promotes metastatic competence in small cell lung cancer. Nat Commun. 2025 May 26; 16(1):4865. Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. PMID: 40419484.
      View in: PubMed   Mentions:    Fields:    
    2. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies. Cancers (Basel). 2025 Apr 25; 17(9). Shah NJ, Sura S, Shinde R, Shi J, Bupathi M, Vickery D, Perini R, Motzer RJ. PMID: 40361361; PMCID: PMC12071004.
      View in: PubMed   Mentions:
    3. How I individualize treatment for chronic-phase CML. Blood. 2025 Apr 16. Leyte-Vidal AM, Shah NP. PMID: 40239150.
      View in: PubMed   Mentions:    Fields:    
    4. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. Eur Urol Oncol. 2025 Mar 29. Kotecha RR, Doshi SD, Knezevic A, Jacobi R, Woo HJ, Aggen DH, McHugh DJ, Shah NJ, Carlo MI, Keegan NM, Gayadin Y, Chaim J, Donoghue MTA, Iyer G, Lee CH, Feldman DR, Motzer RJ, Voss MH. PMID: 40158923.
      View in: PubMed   Mentions:    Fields:    
    5. Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. J Exp Med. 2025 Jan 06; 222(1). Shang J, Del Valle DM, Britton GJ, Mead KR, Rajpal U, Chen-Liaw A, Mogno I, Li Z, Menon R, Gonzalez-Kozlova E, Elkrief A, Peled JU, Gonsalves TR, Shah NJ, Postow M, Colombel JF, Gnjatic S, Faleck DM, Faith JJ. PMID: 39666007; PMCID: PMC11636624.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    6. Esophagectomy may have a role in stage IV esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2024 Nov 22. Sewell M, Toumbacaris N, Tan KS, Bahadur N, Philip J, Shah NJ, Niederhausern A, Tavarez Martinez C, Zheng H, Boerner T, Janjigian YY, Maron SB, Bott MJ, Gray KD, Park BJ, Sihag S, Jones DR, Ku GY, Wu AJ, Molena D. PMID: 39581309; PMCID: PMC12095601.
      View in: PubMed   Mentions:    Fields:    
    7. The promise of allosteric kinase inhibition. Blood. 2024 Nov 07; 144(19):1975-1976. Shah NP. PMID: 39509121.
      View in: PubMed   Mentions:    Fields:    
    8. Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]. Eur Urol. 2025 Jan; 87(1):96. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. PMID: 39426859.
      View in: PubMed   Mentions:    Fields:    
    9. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024 08 08; 144(6):639-645. Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, Miller KB, Hu F, Mase A, Shan Y, Hantschel O, Jacobson MP, Shah NP. PMID: 38643492.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    10. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia. 2024 Sep; 38(9):2046-2050. Leyte-Vidal A, DeFilippis R, Outhwaite IR, Kwan I, Lee JY, Leavitt C, Miller KB, Rea D, Rangwala AM, Lou K, Patel S, Alvarez A, Shokat KM, Bahar I, Seeliger MA, Shah NP. PMID: 39085402; PMCID: PMC11347358.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    11. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2024 07 01; 7(7):e2422674. Shah NJ, Shinde R, Moore KJ, Sainski-Nguyen A, Le LB, Cao F, Song R, Singhal P, Motzer RJ. PMID: 39052293; PMCID: PMC11273232.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clin Cancer Res. 2024 Jul 01; 30(13):2822-2834. Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. PMID: 38652814; PMCID: PMC11215405.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials. Cancers (Basel). 2024 Jun 14; 16(12). Shah NJ, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B, Gourna Paleoudis E, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan M, Cheruku D, Lee A, Sridhar A, Hee BTP, Ahn J, Pecora A, Ip A, Atkins MB. PMID: 38927928; PMCID: PMC11202168.
      View in: PubMed   Mentions: 1  
    14. Overcoming Secondary Mutations of Type II Kinase Inhibitors. J Med Chem. 2024 Jun 27; 67(12):9776-9788. Wang X, DeFilippis RA, Yan W, Shah NP, Li HY. PMID: 38837951; PMCID: PMC11586107.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    15. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. Eur Urol. 2024 Aug; 86(2):90-94. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. PMID: 38782695; PMCID: PMC11970537.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    16. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. PMID: 38394770.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    17. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 03; 38(3):475-481. Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, Chuah C, DeAngelo DJ, Hochhaus A, Lipton JH, Mauro M, Nicolini F, Pinilla-Ibarz J, Rosti G, Rousselot P, Shah NP, Talpaz M, Vorog A, Ren X, Kantarjian H. PMID: 38287132; PMCID: PMC10912029.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    18. Complex Genomic Rearrangements Involving ETV6::ABL1 Gene Fusion in an Individual with Myeloid Neoplasm. Genes (Basel). 2023 09 23; 14(10). Qi Z, Smith C, Shah NP, Yu J. PMID: 37895201; PMCID: PMC10606058.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 09; 202(5):942-952. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. PMID: 37246588; PMCID: PMC10524617.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 01 11; 114(1):160-164. Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. PMID: 34491344; PMCID: PMC8755495.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea. J Crohns Colitis. 2021 Oct 07; 15(10):1679-1685. Norsa L, Berni Canani R, Duclaux-Loras R, Bequet E, Köglmeier J, Russell RK, Uhlig HH, Travis S, Hollis J, Koletzko S, Grimaldi G, Castaldo G, Rodrigues A, Deflandre J, Dembinski L, Shah N, Heinz-Erian P, Janecke A, Leskinen S, Wedenoja S, Koskela R, Lachaux A, Kolho KL, Ruemmele FM. PMID: 33770165.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    22. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021 08 01; 106(8):2242-2245. Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. PMID: 33626861; PMCID: PMC8327742.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clin Cancer Res. 2021 07 15; 27(14):4003-4011. Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, Levine RL, Shah NP. PMID: 34103301; PMCID: PMC8282743.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    24. Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. Nat Commun. 2020 02 21; 11(1):995. Serra EG, Schwerd T, Moutsianas L, Cavounidis A, Fachal L, Pandey S, Kammermeier J, Croft NM, Posovszky C, Rodrigues A, Russell RK, Barakat F, Auth MKH, Heuschkel R, Zilbauer M, Fyderek K, Braegger C, Travis SP, Satsangi J, Parkes M, Thapar N, Ferry H, Matte JC, Gilmour KC, Wedrychowicz A, Sullivan P, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Baeumler TA, Fulga TA, Carrami EM, Ahmed A, Wilson R, Barrett JC, Elkadri A, Griffiths AM, COLORS in IBD group investigators, Oxford IBD cohort study investigators, INTERVAL Study, Swiss IBD cohort investigators, UK IBD Genetics Consortium, NIDDK IBD Genetics Consortium, Snapper SB, Shah N, Muise AM, Wilson DC, Uhlig HH, Anderson CA. PMID: 32081864; PMCID: PMC7035382.
      View in: PubMed   Mentions: 26     Fields:    
    25. Alterations in T and B Cell Receptor Repertoires Patterns in Patients With IL10 Signaling Defects and History of Infantile-Onset IBD. Front Immunol. 2020; 11:109. Werner L, Lee YN, Rechavi E, Lev A, Yerushalmi B, Ling G, Shah N, Uhlig HH, Weiss B, Somech R, Snapper SB, Shouval DS. PMID: 32117262; PMCID: PMC7017840.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    26. Long-term Outcomes of Paediatric Patients Admitted With Acute Severe Colitis- A Multicentre Study From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2019 Dec 10; 13(12):1518-1526. Krauthammer A, Tzivinikos C, Assa A, Miele E, Strisciuglio C, Urlep D, Serban ED, Singh A, Winter HS, Russell RK, Hojsak I, Malham M, Navas-López VM, Croft NM, Lee HM, Ledder O, Shamasneh I, Hussey S, Huynh HQ, Wine E, Shah N, Sladek M, de Meij TG, Romano C, Dipasquale V, Lionetti P, Afzal NA, Aloi M, Lee K, Martín-de-Carpi J, Yerushalmy-Feler A, Subramanian S, Weiss B, Shouval DS. PMID: 31120524.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. Janus kinase inhibition for autoinflammation in patients with DNASE2 deficiency. J Allergy Clin Immunol. 2020 02; 145(2):701-705.e8. Hong Y, Capitani M, Murphy C, Pandey S, Cavounidis A, Takeshita H, Nanthapisal S, Yasuda T, Bader-Meunier B, McCreary D, Omoyinmi E, Rao A, Booth C, Gilmour K, Sebire N, Shah N, Klein N, Bullock AN, Eleftheriou D, Uhlig HH, Brogan P. PMID: 31775019.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020 03; 61(3):650-659. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. PMID: 31647335.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    29. Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: A multi-center case series. Dig Liver Dis. 2019 11; 51(11):1537-1546. Isoldi S, Belsha D, Yeop I, Uc A, Zevit N, Mamula P, Loizides AM, Tabbers M, Cameron D, Day AS, Abu-El-Haija M, Chongsrisawat V, Briars G, Lindley KJ, Koeglmeier J, Shah N, Harper J, Syed SB, Thomson M. PMID: 31358484.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    30. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. Cancer Res. 2019 08 15; 79(16):4283-4292. Apsel Winger B, Cortopassi WA, Garrido Ruiz D, Ding L, Jang K, Leyte-Vidal A, Zhang N, Esteve-Puig R, Jacobson MP, Shah NP. PMID: 31270078; PMCID: PMC6697585.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    31. Sub-10-minute High-quality Diagnostic Colonoscopy With Terminal Ileum Intubation in Children Is Feasible and Safe. J Pediatr Gastroenterol Nutr. 2019 07; 69(1):6-12. Thomson M, Eltumi M, Singh C, Eyles M, Shah N, Vadamalayan B, Chong S, Thapar N, D'Ambrosio A, Isoldi S. PMID: 30889130.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    32. Corrigendum: Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2018 04 27; 12(5):630. Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. PMID: 29562246.
      View in: PubMed   Mentions:    Fields:    
    33. Detecting inflammation in inflammatory bowel disease - how does ultrasound compare to magnetic resonance enterography using standardised scoring systems? Pediatr Radiol. 2018 06; 48(6):843-851. Barber JL, Zambrano-Perez A, Olsen ØE, Kiparissi F, Baycheva M, Knaflez D, Shah N, Watson TA. PMID: 29651607.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    34. Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia. J Clin Oncol. 2018 01 20; 36(3):220-224. Shah NP. PMID: 29206554.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    35. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017 10 01; 11(10):1230-1237. Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. PMID: 28605483.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    36. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. Ann Hematol. 2017 Aug; 96(8):1303-1313. Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. PMID: 28534184; PMCID: PMC5486782.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    37. Iodine Status and Growth in Cow's Milk Allergy. J Pediatr Gastroenterol Nutr. 2017 05; 64(5):655-656. Seward H, Meyer R, Shah N. PMID: 28045784.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    38. Paediatric magnetic resonance enteroclysis under general anaesthesia - initial experience. Pediatr Radiol. 2017 Jun; 47(7):877-883. Sadigh S, Chopra M, Sury MR, Shah N, Olsen ØE, Watson TA. PMID: 28386628.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. Establishing the prevalence of low vitamin D in non-immunoglobulin-E mediated gastrointestinal food allergic children in a tertiary centre. World Allergy Organ J. 2017; 10(1):4. Foong RX, Meyer R, Dziubak R, Lozinsky AC, Godwin H, Reeve K, Hussain ST, Nourzaie R, Shah N. PMID: 28101293; PMCID: PMC5225666.
      View in: PubMed   Mentions: 8  
    40. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512. Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. PMID: 27956535.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    41. The impact of the elimination diet on growth and nutrient intake in children with food protein induced gastrointestinal allergies. Clin Transl Allergy. 2016; 6:25. Meyer R, De Koker C, Dziubak R, Godwin H, Dominguez-Ortega G, Chebar Lozinsky A, Skrapac AK, Gholmie Y, Reeve K, Shah N. PMID: 27418957; PMCID: PMC4944436.
      View in: PubMed   Mentions: 26  
    42. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016 09; 91(9):869-74. Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. PMID: 27192969; PMCID: PMC5094534.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    43. Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years. J Crohns Colitis. 2017 Jan; 11(1):60-69. Kammermeier J, Dziubak R, Pescarin M, Drury S, Godwin H, Reeve K, Chadokufa S, Huggett B, Sider S, James C, Acton N, Cernat E, Gasparetto M, Noble-Jamieson G, Kiparissi F, Elawad M, Beales PL, Sebire NJ, Gilmour K, Uhlig HH, Bacchelli C, Shah N. PMID: 27302973; PMCID: PMC5885808.
      View in: PubMed   Mentions: 55     Fields:    
    44. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016 07 10; 34(20):2333-40. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. PMID: 27217448; PMCID: PMC5118045.
      View in: PubMed   Mentions: 379     Fields:    Translation:HumansCTClinical Trials
    45. Histopathological features of gastrointestinal mucosal biopsies in children with juvenile idiopathic arthritis. Pediatr Res. 2016 06; 79(6):895-901. Pichler J, Ong C, Shah N, Sebire N, Kiparrissi F, Borrelli O, Pilkington C, Elawad M. PMID: 26882369.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. Detecting inflammation in the unprepared pediatric colon - how reliable is magnetic resonance enterography? Pediatr Radiol. 2016 May; 46(5):646-52. Barber JL, Lozinsky AC, Kiparissi F, Shah N, Watson TA. PMID: 26867608.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2015 Dec; 27(12):1425-8. Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M. PMID: 26426835.
      View in: PubMed   Mentions: 5  Translation:Humans
    48. Systematic review of the impact of feed protein type and degree of hydrolysis on gastric emptying in children. BMC Gastroenterol. 2015 Oct 15; 15:137. Meyer R, Foong RX, Thapar N, Kritas S, Shah N. PMID: 26472544; PMCID: PMC4608328.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    49. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015 Nov; 90(11):1060-4. Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, Guha M, Rea D, Peacock A. PMID: 26284693.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    50. PPARγ: Welcoming the New Kid on the CML Stem Cell Block. Cancer Cell. 2015 Oct 12; 28(4):409-411. Apsel Winger B, Shah NP. PMID: 26461088.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    51. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Rep. 2015 Sep 30; 5:14538. Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. PMID: 26419724; PMCID: PMC4588578.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    52. Time to symptom improvement using elimination diets in non-IgE-mediated gastrointestinal food allergies. Pediatr Allergy Immunol. 2015 Aug; 26(5):403-8. Lozinsky AC, Meyer R, De Koker C, Dziubak R, Godwin H, Reeve K, Dominguez Ortega G, Shah N. PMID: 25963794.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    53. Cow's Milk Protein Allergy from Diagnosis to Management: A Very Different Journey for General Practitioners and Parents. Children (Basel). 2015 Jul 21; 2(3):317-29. Lozinsky AC, Meyer R, Anagnostou K, Dziubak R, Reeve K, Godwin H, Fox AT, Shah N. PMID: 27417366; PMCID: PMC4928770.
      View in: PubMed   Mentions: 18  
    54. Histological findings in infants with Gastrointestinal food allergy are associated with specific gastrointestinal symptoms; retrospective review from a tertiary centre. BMC Clin Pathol. 2015; 15:12. Shah N, Foong RM, Borrelli O, Volonaki E, Dziubak R, Meyer R, Elawad M, Sebire NJ. PMID: 26085814; PMCID: PMC4469460.
      View in: PubMed   Mentions: 2  
    55. Nutritional status in children with Shwachman-diamond syndrome. Pancreas. 2015 May; 44(4):590-5. Pichler J, Meyer R, Köglmeier J, Ancliff P, Shah N. PMID: 25742431.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    56. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer Discov. 2015 Jun; 5(6):668-79. Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. PMID: 25847190; PMCID: PMC4522415.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    57. A practical approach to vitamin and mineral supplementation in food allergic children. Clin Transl Allergy. 2015; 5:11. Meyer R, De Koker C, Dziubak R, Skrapac AK, Godwin H, Reeve K, Chebar-Lozinsky A, Shah N. PMID: 25780558; PMCID: PMC4361144.
      View in: PubMed   Mentions: 15  
    58. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife. 2014 Dec 22; 3. Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. PMID: 25531068; PMCID: PMC4307180.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    59. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep. 2014 Nov 20; 9(4):1333-48. Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. PMID: 25456130; PMCID: PMC4380442.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    60. Dietary elimination of children with food protein induced gastrointestinal allergy - micronutrient adequacy with and without a hypoallergenic formula? Clin Transl Allergy. 2014; 4(1):31. Meyer R, De Koker C, Dziubak R, Godwin H, Dominguez-Ortega G, Shah N. PMID: 25328667; PMCID: PMC4201676.
      View in: PubMed   Mentions: 17  
    61. Feeding difficulties in children with food protein-induced gastrointestinal allergies. J Gastroenterol Hepatol. 2014 Oct; 29(10):1764-9. Meyer R, Rommel N, Van Oudenhove L, Fleming C, Dziubak R, Shah N. PMID: 24720353.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    62. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. J Crohns Colitis. 2014 Dec; 8(12):1730-4. Mutalib M, Borrelli O, Blackstock S, Kiparissi F, Elawad M, Shah N, Lindley K. PMID: 25240477.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    63. Targeted gene panel sequencing in children with very early onset inflammatory bowel disease--evaluation and prospective analysis. J Med Genet. 2014 Nov; 51(11):748-55. Kammermeier J, Drury S, James CT, Dziubak R, Ocaka L, Elawad M, Beales P, Lench N, Uhlig HH, Bacchelli C, Shah N. PMID: 25194001.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    64. Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. ACS Nano. 2014 Sep 23; 8(9):9199-208. Tajon CA, Seo D, Asmussen J, Shah N, Jun YW, Craik CS. PMID: 25166742; PMCID: PMC4174091.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    65. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014 Nov; 147(5):990-1007.e3. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM, COLORS in IBD Study Group and NEOPICS. PMID: 25058236; PMCID: PMC5376484.
      View in: PubMed   Mentions: 247     Fields:    
    66. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014 Apr 08; 111(14):5319-24. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. PMID: 24623852; PMCID: PMC3986131.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCells
    67. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014 Apr 10; 123(15):2317-24. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. PMID: 24569263; PMCID: PMC4915794.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    68. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov. 2014 Feb; 4(2):200-15. Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. PMID: 24362263; PMCID: PMC4248023.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    69. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22. Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. PMID: 24374145; PMCID: PMC4414320.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    70. What does a deep molecular response signify? J Clin Oncol. 2014 Feb 10; 32(5):471-4. Politi J, Shah NP. PMID: 24297955.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group. Inflamm Bowel Dis. 2013 Dec; 19(13):2820-8. Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, Guariso G, Canioni D, Lambot K, Talbotec C, Shah N, Begue B, Rieux-Laucat F, Goulet O, Cerf-Bensussan N, Neven B, Ruemmele FM. PMID: 24216686.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    72. Duodenal haematoma following endoscopy as a marker of coagulopathy. Pediatr Radiol. 2014 Apr; 44(4):392-7. Hameed S, McHugh K, Shah N, Arthurs OJ. PMID: 24292805.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw. 2013 Nov; 11(11):1327-40. O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H, Ntational comprehensive cancer network. PMID: 24225967; PMCID: PMC4234105.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    74. The role of pre- and probiotics in infant nutrition. J Fam Health Care. 2013 Oct-Nov; 23(7):25-9. Meyer R, Shah N. PMID: 24383277.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Manifestations of food protein induced gastrointestinal allergies presenting to a single tertiary paediatric gastroenterology unit. World Allergy Organ J. 2013 Aug 06; 6(1):13. Meyer R, Fleming C, Dominguez-Ortega G, Lindley K, Michaelis L, Thapar N, Elawad M, Chakravarti V, Fox AT, Shah N. PMID: 23919257; PMCID: PMC3828665.
      View in: PubMed   Mentions: 19  
    76. The role of endoscopy and biopsy in the management of severe gastrointestinal disease in cystic fibrosis patients. Pediatr Pulmonol. 2013 Dec; 48(12):1181-9. Shah N, Tan HL, Sebire N, Suri R, Leuven K. PMID: 23825099.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    77. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013 Apr 18; 121(16):3165-71. Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. PMID: 23430109; PMCID: PMC3630831.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    78. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2013; 313-8. Smith CC, Shah NP. PMID: 23714533.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    79. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013 Mar; 131(3):825-30. Engelhardt KR, Shah N, Faizura-Yeop I, Kocacik Uygun DF, Frede N, Muise AM, Shteyer E, Filiz S, Chee R, Elawad M, Hartmann B, Arkwright PD, Dvorak C, Klein C, Puck JM, Grimbacher B, Glocker EO. PMID: 23158016.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    80. Front-line TKI therapy for chronic-phase CML: the luxury of choice. Oncology (Williston Park). 2012 Oct; 26(10):908, 910, 912. Shah NP. PMID: 23175996.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep. 2012 Oct; 12(5):373-9. Shah N, Kammermeier J, Elawad M, Glocker EO. PMID: 22890722.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    82. Gastrointestinal endoscopy and mucosal biopsy in the first year of life: indications and outcome. J Pediatr Gastroenterol Nutr. 2012 Jul; 55(1):62-5. Volonaki E, Sebire NJ, Borrelli O, Lindley KJ, Elawad M, Thapar N, Shah N. PMID: 22210413.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    83. Cow's milk challenge increases weakly acidic reflux in children with cow's milk allergy and gastroesophageal reflux disease. J Pediatr. 2012 Sep; 161(3):476-481.e1. Borrelli O, Mancini V, Thapar N, Giorgio V, Elawad M, Hill S, Shah N, Lindley KJ. PMID: 22513270.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    84. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012 Apr 15; 485(7397):260-3. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. PMID: 22504184; PMCID: PMC3390926.
      View in: PubMed   Mentions: 362     Fields:    Translation:HumansCells
    85. Advancing the STATus of MPN pathogenesis. Blood. 2012 Apr 12; 119(15):3374-6. Shah NP, Shannon K. PMID: 22500049.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    86. Practical dietary management of protein energy malnutrition in young children with cow's milk protein allergy. Pediatr Allergy Immunol. 2012 Jun; 23(4):307-14. Meyer R, Venter C, Fox AT, Shah N. PMID: 22435534.
      View in: PubMed   Mentions: 12     Fields:    
    87. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2012; 685-9. Smith CC, Shah NP. PMID: 24451819.
      View in: PubMed   Mentions:    Fields:    
    88. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia. Clin Adv Hematol Oncol. 2011 Dec; 9(12):925-6. Shah NP. PMID: 22252660.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    89. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci. 2011 Dec; 1246:102-7. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. PMID: 22236434.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    90. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clin Cancer Res. 2011 Nov 01; 17(21):6605-7. Smith CC, Shah NP. PMID: 21948230.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    91. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011 Oct 24; 208(11):2163-74. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, Shah NP, Melnick AM, Müschen M. PMID: 21911423; PMCID: PMC3201200.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimalsCells
    92. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011; 2011:121-7. Smith CC, Shah NP. PMID: 22160023.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    93. Infant colitis--it's in the genes. Lancet. 2010 Oct 09; 376(9748):1272. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, Grimbacher B. PMID: 20934598.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    94. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010 Mar; 85(3):164-70. Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G. PMID: 20131302.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    95. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb; 95(2):232-40. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. PMID: 20139391; PMCID: PMC2817025.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    96. Fine-tuning targeted therapy of CML. Blood. 2009 Dec 03; 114(24):4914-5. Shah NP. PMID: 19965702.
      View in: PubMed   Mentions:    Fields:    
    97. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009 Nov 19; 361(21):2033-45. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. PMID: 19890111; PMCID: PMC2787406.
      View in: PubMed   Mentions: 558     Fields:    
    98. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res. 2010 Jun; 34(6):708-13. Paquette RL, Nicoll J, Chalukya M, Gondek L, Jasek M, Sawyers CL, Shah NP, Maciejewski J. PMID: 19804904; PMCID: PMC5821258.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    99. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 2009 Sep 15; 115(18):4136-47. Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. PMID: 19536906; PMCID: PMC5345391.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    100. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009 Mar 15; 69(6):2384-92. Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. PMID: 19276351; PMCID: PMC2678021.
      View in: PubMed   Mentions: 63     Fields:    
    101. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 09; 14(6):485-93. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. PMID: 19061839.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    102. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 01; 26(19):3204-12. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. PMID: 18541900.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCTClinical Trials
    103. Successful treatment of extensive infantile hemangiomatosis of the small bowel in a 3-month-old with thalidomide and somatostatin analog. J Pediatr Gastroenterol Nutr. 2008 May; 46(5):593-7. Jarvi K, Roebuck DJ, Sebire NJ, Lindley K, Shah N, Salomon J, Curry JI. PMID: 18493217.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    104. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. PMID: 18401416.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    105. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 2:S31-S36. Shah NP. PMID: 18397679.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    106. Treatment of intractable ulcerating enterocolitis of infancy by allogeneic bone marrow transplantation. Clin Gastroenterol Hepatol. 2008 Feb; 6(2):248-50. Thapar N, Lindley KJ, Kiparissi F, Elawad MA, Ashworth M, Veys P, Gaspar HB, Hill SM, Milla PJ, Shah N. PMID: 18187369.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    107. Progressive thoughts about progressive disease. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5229-31. Shah NP. PMID: 17875748.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    108. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007 Sep; 117(9):2562-9. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. PMID: 17710227; PMCID: PMC1940237.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    109. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007 Jun 15; 109(12):5143-50. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N. PMID: 17317857.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    110. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood. 2007 Apr 15; 109(8):3400-8. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB. PMID: 17209055; PMCID: PMC1852258.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    111. Dasatinib. Drugs Today (Barc). 2007 Jan; 43(1):5-12. Shah NP. PMID: 17315048.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    112. Medical management of CML. Hematology Am Soc Hematol Educ Program. 2007; 371-5. Shah NP. PMID: 18024653.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    113. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15; 109(8):3207-13. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. PMID: 17185463.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    114. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15; 109(6):2303-9. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. PMID: 17138817.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    115. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006 Feb 21; 103(8):2794-9. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. PMID: 16477019; PMCID: PMC1413797.
      View in: PubMed   Mentions: 209     Fields:    Translation:Humans
    116. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006 Jan 15; 66(2):1007-14. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. PMID: 16424036.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    117. Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. PMID: 15988530.
      View in: PubMed   Mentions: 256     Fields:    Translation:HumansCells
    118. Long-term outcome of intractable ulcerating enterocolitis of infancy. J Pediatr Gastroenterol Nutr. 2005 May; 40(5):582-8. Thapar N, Shah N, Ramsay AD, Lindley KJ, Milla PJ. PMID: 15861020.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    119. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005; 183-7. Shah NP. PMID: 16304378.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    120. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood. 2005 Mar 01; 105(5):2093-8. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R. PMID: 15345592.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    121. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16; 305(5682):399-401. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. PMID: 15256671.
      View in: PubMed   Mentions: 447     Fields:    Translation:HumansAnimalsCells
    122. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003 Oct 20; 22(47):7389-95. Shah NP, Sawyers CL. PMID: 14576846.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    123. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug; 2(2):117-25. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL. PMID: 12204532.
      View in: PubMed   Mentions: 461     Fields:    Translation:HumansCells
    124. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A. 2002 Aug 06; 99(16):10700-5. Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. PMID: 12149456; PMCID: PMC125018.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    Neil Pravin's Networks
    Concepts (450)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.